Browsing Tag
Multiple System Atrophy
7 posts
Can Alterity Therapeutics’ penny stock (ASX: ATH) ride ATH434’s $2.4bn market potential to long-term gains?
Alterity Therapeutics eyes $2.4B peak sales for ATH434 in Multiple System Atrophy. Can this small-cap biotech turn clinical promise into commercial reality?
Theravance completes enrollment in Phase 3 CYPRESS trial for ampreloxetine in MSA-related nOH
Theravance completes Phase 3 enrollment for ampreloxetine in MSA-related nOH. Topline data expected in Q1 2026. Could this be a rare disease breakthrough?
Alterity Therapeutics stock surges 33% after ATH434 momentum and FDA fast track designation
Alterity Therapeutics surged 33% after highlighting ATH434’s Phase 2 gains and FDA Fast Track status. Find out why investors are piling in now.
BioArctic advances exidavnemab phase 2a cohorts after safety review
BioArctic expands its Phase 2a trial for exidavnemab after a successful safety review. Read how this impacts Parkinson’s and MSA drug development today.
Alterity Therapeutics launches phase 2 trial of MSA candidate ATH434
Alterity Therapeutics said that it has launched a phase 2 clinical trial of its lead candidate ATH434 in…
Biohaven secures orphan drug status for verdiperstat in MSA treatment
Connecticut-based Biohaven Pharmaceutical has received a significant regulatory boost, with the US FDA granting orphan drug designation for…
Prana Biotechnology secures FDA orphan drug status for PBT434 to treat multiple system atrophy
In a significant milestone, Prana Biotechnology, an Australian biotech company, has obtained Orphan Drug designation from the FDA…